Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
U.K. Bonds: the Election’s Impact on the Market
28:51 - UBS Head of U.K. Rates Strategy John Wraith discusses the U.K. elections and their impact on the bond market. He speaks to Bloomberg’s Manus Cranny and Mark Barton on “Countdown.” (Source: Bloomberg)
  • Will Take 325 Seats to Get Anything Done: Lea
  • Crude Rise Surprise
  • How Have U.K. Assets Performed Since 2010 Election?